SEOM Clinical Guideline of localized rectal cancer (2016)

• E. González-Flores ^[7] ; F. Losa ^[8] ; C. Pericay ^[9] ; E. Polo ^[1] ; S. Roselló ^[2] ; M. J. Safont ^[3] ; R. Vera ^[4] ; J. Aparicio ^[10] ; M. T. Cano ^[5] ; C. Fernández-Martos ^[6]
  1. [1] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  2. [2] Hospital Clinico Universitario de Valencia

     Hospital Clinico Universitario de Valencia

     Valencia, España

     
  3. [3] Hospital General Universitario de Valencia

     Hospital General Universitario de Valencia

     Valencia, España

     
  4. [4] Gobierno de Navarra

     Gobierno de Navarra

     Pamplona, España

     
  5. [5] Hospital Reina Sofía

     Hospital Reina Sofía

     Tudela, España

     
  6. [6] Instituto Valenciano de Oncologia

     Instituto Valenciano de Oncologia

     Valencia, España

     
  7. [7] Complejo Hospitalario de Granada, España
  8. [8] Hospital Sant Joan Despí-Moises Broggi-ICO Hospitalet, España
  9. [9] Hospital Parc Taulí de Sabadell, España
  10. [10] Hospital Universitario La Fe de Valencia, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 12 (December 2016), 2016, págs. 1163-1171
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Localized rectal adenocarcinoma is a heterogeneous disease and current treatment recommendations are based on a preoperative multidisciplinary evaluation. High-resolution magnetic resonance imaging and endoscopic ultrasound are complementary to do a locoregional accurate staging. Surgery remains the mainstay of treatment and preoperative therapies with chemoradiation (CRT) or short-course radiation (SCRT) must be considered in more locally advanced cases. Novel strategies with induction chemotherapy alone or preceding or after CRT (SCRT) and surgery are in development.